FDA approves deucravacitinib for plaque psoriasis
ADC评论
September 12, 2022
On September 10, Bristol-Myers Squibb (BMS) announced that the marketing application of its TYK2 inhibitor deucravacitinib for the treatment of plaque psoriasis has been approved
